Abstract
The main revisions to the item of medical treatment in the 2015 edition of the Guidelines for Prevention and Treatment of Osteoporosis are the additions of the drugs such as ibandronate, teriparatide acetate (once-weekly preparation), and denosumab, which were approved after the release of the 2011 edition, and of information on new dosage forms for existing drugs. Furthermore, the heading "Evaluation and Recommendations" for each drug was changed to "Evaluation of Efficacy" . The choice of drug is determined based on evidence for the effectiveness of each drug and in accordance with the age, fracture risk, and pathophysiology of each patient. As for the selection and combined use of the various drugs, accumulation of evidence is anticipated, but sequential therapy using antiresorptive agents following treatment with teriparatide preparations is recommended.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
